INBX
HEALTHCAREInhibrx Biosciences Inc
$141.84+13.72 (+10.71%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INBX Today?
No stock-specific AI insight has been generated for INBX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.84$155.29
$141.84
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-9.04
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume774K
Avg Volume (10D)—
Shares Outstanding14.6M
INBX News
20 articles- Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCCYahoo Finance·May 8, 2026
- Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory MomentumYahoo Finance·May 2, 2026
- Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA PlansYahoo Finance·Apr 26, 2026
- Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal CancerMarketbeat·Apr 25, 2026
- INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer StudyYahoo Finance·Apr 23, 2026
- Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares FallYahoo Finance·Apr 22, 2026
- Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerYahoo Finance·Apr 21, 2026
- Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerYahoo Finance·Apr 20, 2026
- Coinbase downgraded, Deere upgraded: Wall Street's top analyst callsYahoo Finance·Apr 8, 2026
- Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- Inhibrx Announces Participation in Upcoming Scientific ConferenceYahoo Finance·Mar 2, 2026
- Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data ReadoutsYahoo Finance·Dec 28, 2025
- Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone UpdatesYahoo Finance·Dec 18, 2025
- Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) ProgramYahoo Finance·Dec 16, 2025
- Inhibrx Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- LGND: Target Up On Improved Growth OutlookYahoo Finance·Nov 10, 2025
- Inhibrx Announces Participation in Upcoming Scientific ConferencesYahoo Finance·Nov 4, 2025
- Evaluating Inhibrx Biosciences (INBX) Valuation Following Breakthrough Phase 2 Results for OzekibartYahoo Finance·Oct 26, 2025
- Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victoryClinicaltrialsarena·Oct 24, 2025
- Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion CohortsYahoo Finance·Oct 23, 2025
All 20 articles loaded
Price Data
Open$128.70
Previous Close$128.12
Day High$142.12
Day Low$127.25
52 Week High$155.29
52 Week Low$10.84
52-Week Range
$10.84$155.29
$141.84
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-9.04
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume774K
Avg Volume (10D)—
Shares Outstanding14.6M
About Inhibrx Biosciences Inc
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—